Form 4: Establishment Labs CFO Raj Denhoy Receives Stock and Option Awards

Raj Denhoy, CFO of Establishment Labs, reports the acquisition of stock units and stock options, signaling continued alignment with the company's long-term performance.

Summary

• Raj Denhoy, the Chief Financial Officer of Establishment Labs Holdings Inc., reported changes in beneficial ownership on March 19, 2024.
• On March 6, 2024, Denhoy acquired 5,644 common shares under the Issuer's 2018 Equity Incentive Plan at a price of $0.
• These shares vest in equal installments annually, starting March 6, 2025, contingent upon continued service.
• Additionally, Denhoy acquired options to purchase 8,030 common shares at an exercise price of $49.25, also vesting annually from March 6, 2025, subject to continued service.
• Following these transactions, Denhoy directly owns 13,447 common shares and options for 8,030 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of stock and options to the CFO is a routine event and signals confidence in the company's future. The vesting schedule promotes long-term alignment.

Positives

• The grant of stock units and options to the CFO aligns his interests with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the CFO.

Risks

• The value of the stock units and options is dependent on the future performance of Establishment Labs' stock.
• If the CFO leaves the company before the vesting dates, the unvested shares and options will be forfeited.

Future Outlook

The vesting schedule of the stock units and options suggests an expectation of continued service and contribution from the CFO over the next four years.

Industry Context

Stock and option grants are a common practice in the biotech and medical device industries to incentivize and retain key executives. This grant aligns Establishment Labs with industry norms for executive compensation.

Comparison to Industry Standards

• Comparing Establishment Labs' equity compensation practices to similar medical device companies like InMode or Sientra reveals that such grants are standard practice.
• The vesting schedules and option pricing are generally in line with industry benchmarks for executive compensation packages.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with theirs.
• Employees may see this as a sign of stability and commitment from the company to its leadership.

Key Dates